Business Wire

MYPINPAD Achieves PCI SSC SPOC Approval for IOS Devices

7.1.2020 03:01:00 EET | Business Wire | Press release

Share

MYPINPAD (“MPP”), the global leader in secure personal authentication for payment solutions, has achieved Payment Card Industry (PCI) Security Standards Council certification for its iOS Software based PIN entry on a Commercial off-the-shelf (SPoC) solution.

The UK based fintech company is amongst the world’s first to achieve certification for its innovative PIN on Mobile solution (“MPP mPOS”), evaluated by Brightsight. The solution enables everyday smartphones and tablets to replace traditional Point of Sale terminals and PIN entry mPOS devices.

MYPINPAD’s innovative SPoC solution is seen as a major enabler for the predicted massive expansion in the number of payment acceptance devices globally. The solution is easily integrated into 3rd party applications and can be delivered ‘As-a-Service’.

The cost of hardware-based PIN pads is seen as a significant barrier to global card acceptance adoption. MPP mPOS will enable even the smallest of enterprises and those in under-served economies to accept card payments, while also relieving merchants and larger retailers from the burden of purchasing and maintaining large estates of traditional POS terminals.

Importantly, PIN entry is via a standard PIN pad image (not scrambled), ensuring seamless customer adoption. The technology supports use by people with visual impairment and people with other disabilities, which is critical in certain markets, delivering the world’s first fully inclusive solution.

Phil King, CEO and Chairman, MYPINPAD, said: “MYPINPAD has been at the forefront of the thinking about and the development of PIN on Mobile since 2012. We are proud to have achieved PCI SPoC certification for IOS devices, featuring a standard non-scrambled PIN pad that consumers trust and are familiar with. We look forward to announcing the same for Android devices soon.

Since inception MYPINPAD’s commitment to this technology has been unwavering. Our platform has been designed to make available Secure Card Reader-based and contactless payment acceptance solutions, the latter called MPP SoftPOS as a software only solution, with attestation and with the pre-integration of our code inside every payShield HSM. We look forward to being able to offer on a global basis PCI SPoC certified MPP mPOS on all devices and scheme approved MPP SoftPOS on Android devices in the new year.”

"It is a pleasure to work with the creative and skilled MYPINPAD team and help bring new and innovative payment solutions to market. We look forward in continuing our partnership with MYPINPAD in the years to come." says Rob van Marrewijk, Director Business Development at Brightsight.

***ENDS***

About MYPINPAD:

MYPINPAD is a global leader in secure personal authentication for payment solutions residing on commercially available smartphones and tablets. Our proprietary and globally patented technology secures and protects the input of sensitive information on touchscreens creating a trusted environment. MYPINPAD’s innovative solution set removes the reliance on specialised hardware for personal authentication; reduces cost and complexity, promotes rapid adoption and leverages the connected capabilities of smart devices.

Please visit www.mypinpad.com to discover more about this transformational technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Becky Sales
becky@skyparlour.com
07803204780

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye